AbbVie, Inc. Chris Glotzbach, Tom Van Spankeren and Jeffrey Li October 23, 2014 Agenda 1. 2. 3. 4. 5. 6. 7. 8. Introduction Macroeconomic Review Relevant Stock Market Prospects Company Review Financial Analysis Financial Projection Application of Valuation Methodologies Recommendation Introduction - Spin-off of Abbott Laboratories (2013) - Research based pharmaceutical company - 8th largest publicly traded pharmeceutical - Employs 25,000 worldwide - Drugs are sold in over 170 Countries Source: AbbVie, Inc. 10-K (Fiscal 2013) page 5, 10 16, Position - Listed on NYSE - ABBV - 400 shares - 200 shares @ $27.08 - 100 shares @ $27.53 - 100 shares @ $34.22 - Cost Basis = $28.98 ($11,592) - Current Price = $56.90 ($22,760) Industry Trends - Worldwide total prescription drug sales projected at 5.1% CAGR until 2020 - $749 Billion $1.05 trillion by 2020 - Biologicals are increasing! From 22% to almost 30% of total pharmaceuticals by 2020 - AbbVie has 7% market share of biologicals - Less patent approvals by F.D.A. - Intellectual Property Rights - 2.3% market share of total prescriptions - Substantial M+A activity - Example: Valeant wants to buy Allergan (Botox) Source: EvaluatePharma Outlook to 2020, Page 3 & 7 Target Market and Demographics - Overall trend in demographics favorable for AbbVie - Emerging markets in focus - Increase emphasis on disease prevention Source: Age invaders, The Economist April 26 2014 Government Regulation - Biologics Price Competition and Innovation Act signed by President Obama in 2009 and vastly amended with the Affordable Care Act - Makes “biosimilars” very difficult to duplicate - They need to be “safe secure and potent” - However uncertainty exists with this legislation - AbbVie petitioned F.D.A. not to approve biosimilars for Humira Source: AbbVie, Inc. 10-K (Fiscal 2013) Page 9 Porter’s Five Forces - Threat of Substitutes: Moderate Generics Threat of New Entrants: Low High R&D barrier Bargaining Power of Suppliers: Low But… Bargaining Power of Buyers: Low Dependent Rivalry: High Attractive market S.W.O.T. Analysis - Strengths: Pipeline - Weaknesses: Fragile Drug Patent - Opportunities: Hep C, Breast Cancer, MS - Threats: Competition Source: Biopharmaceuticals in Perspective Page 52 Where in the Growth Cycle? Growth Phase Source: Graph Template from QuickMBA Guidance and Mgt “Last month, we raised our 2014 earnings-pershare guidance, reflecting strong underlying business performance. We continue to expect positive trends for the second half of the year, as well as additional progress from our pipeline, including the expected U.S. approval of our interferon-free HCV combination.“-CEO Richard Gonzalez 7/25/2014 “I wanted to send a note saying that I’m more energized than ever about our two companies coming together”-CEO Richard Gonzalez 9/29/2014 Source: AbbVie, Inc. FINANCIAL RELEASE 2014 Q2, AbbVie Tells Shire Employees: The Merger Will Go On , WSJ Sept 29,2014 Products - Total Revenue For Fiscal 2013 (in Millions) Total = 18,790 Humira 56.73% USA International Androgel 5.51% Kaletra 5.12% 46% 54% Lupron 4.4% Synthroid 3.31% Sevoflurance 3.02% Other 17.73% Source: AbbVie, Inc. 10-K (Fiscal 2013) Page 45 Humira - Uses: Rheumatoid arthritis, Chrohn’s disease and various other ailments/diseases - 26.2% year over year sales growth - Costs approximately $2,246 a month - 3rd largest sales in US - AbbVie must diversify away from Humira Source: AbbVie, Inc. 10-K (Fiscal 2013) Page 6-15 Patents? - Loses US Humira patent in December 2016 and European patent in April 2018 - Concerned considering it is blockbuster drug - Lack of clarity regarding biosimilar patents - Will it be similar to Niaspan and Tricor/Triliplex where sales declined 90%? Source: AbbVie, Inc. 10-K (Fiscal 2013) Page 6-15 Research & Development - 2013: Just < $3 Billion or 15% of Sales Source: AbbVie, Inc. 10-K (Fiscal 2013) Page 57, AbbVie R&D Page AbbVie’s Pipeline - Hepatitis C – Phase III. Accepted by FDA - Priority Review. Europe Accelerated Review Breast Cancer - Phase III - Clinical Trial Multiple Sclerosis – Daclizumab – Biogenic - Phase III DECIDE Trial Source: AbbVie, Inc. 10-K (Fiscal 2013) Pages 41,41,47 Global Data, AbbVie Financial Analysis Hepatitis C - “In our clinical trials, we're seeing the majority of patients - even up to 100 percent of patients experiencing a cure. And patients are able to tolerate the therapy very well, with fewer than 2.3 percent having to discontinue treatment due to adverse events.” – CEO Richard Gonzalez - 130-150 million worldwide with Hepatitis C - 3.2 million Americans and 17.5 million Europeans - Competition from Gilead’s Sovaldi (already in market) and Merck 15%-20% Discount Source: AbbVie Annual Stockholder Meeting May 9, 2014, World Health Organization; Hepatitis C Fact Sheet , Viral Hepatitis Action Coalition Risks for AbbVie - Creation of biosimilars Humira patent loss Inability to gain market share – Hepatitis C Research and Development efforts are not sufficient - Loss of shareholder trust with management Source: AbbVie, Inc. 10-K (Fiscal 2013) Page 16 -26 Shire Deal? - $55 Billion Pros: - “Would diversify itself internationally” - ADD and ADHD drug totaling 25% of revenues, rare diseases drugs - Tax rate falls to 13% from 22% $8 billion savings in 15 years Cons: - New inversion laws - Huge premium being paid - Shire stock tumbled 30% at deal fallout - $1.64 billion breakup fee – tax deductible Source: AbbVie to Buy Shire for $54 Billion WSJ July 18 2014 Collapse of AbbVie-Shire Deal Leaves Scars WSJ, oct 16 2014 Technical Analysis Source: Fidelity Investments Ratio Analysis DuPont Analysis 1.20 9.00 8.00 1.00 Greenblatt 2011A 7.00 0.80 2012A 2013A 0.56 0.82 0.89 0.40 EBIT/EV NA 9.2% 6% 0.20 0.00 2010 2013A Debt/Assets NA 0.54 0.49 InterestCoverage -181.00 69.25 20.37 Tax Burden Interest Burden 5.00 0.60 EBIT/Tangible Assets Leverage Ratios 2011A 2012A 6.00 4.00 3.00 2.00 1.00 2011 2012 Operating Profit Margin Asset Turnover Leverage TA/ TE 0.00 2013 DuPont Analysis 2010A 2011A 2012A 2013A Tax Burden 0.86 0.94 0.92 0.77 Interest Burden 1.03 1.01 0.98 0.94 Operating Margin 30% 21% 32% 30% Asset Turnover 0.74 0.89 0.68 0.64 Leverage 1.35 1.64 8.03 6.50 ROE 27% 29% 157% 92% Cost of Capital Beta Beta from Yahoo 1 Year Half Year (Annualized) ABT Beta Adj Beta Return to Owner 1.93 1.43 1.38 0.86 1.41 CAPM Risk Free Rate Market Premium CAPM 1 Year 20% Half Year (Annualized) 11% Adj ABBV Return to Owner 14% Graham Growth Rate 2.40% 6% 10% Cost of Equity ABBV Return to Owner Graham Implied g% CAPM Cost of Equity Trailing P/E 22.05 Graham Implied g% 6.78% % Allocate 14% 33% 6.78% 33% 10% 33% 10.3% 100% Cost of Capital Debt Equity Total Financing Capital Structure $14,292.00 87493.12 $101,785.12 Discount Rate 14.0% 86.0% 100% Cost of Equity % Allocate 10.3% 100% Pre Tax - Cost of Debt Tax Rate After Tax - Cost of Debt 2.49% 22% 2% Cost of Equity After Tax - Cost of Debt WACC Risk Premium Discount Rate 10.3% 2% 9.1% 1.0% 10.1% 86.0% 14.0% Revenue Projection - Revenue projection: Major Product Revenue Estimation - Gross Profit Margin: 78% - SG&A: 28.46% - Research and development : 15% - Tax Rate: 22% Revenue Projection Growth rate HUMIRA US HUMIRA Inter HUMIRA Total AndroGel US Kaletra Total Synagis Total Lupron Total Synthroid Total Sevoflurane Total Creon Total Duodopa Total Dyslipidemia Total Other HCV Drug Total 2012A 2013A 2014E 2015E 2016E 2017E 2018E 27.7% 19.6% 25.0% 25.0% 22.0% -15.0% -5.0% 8.5% 10.9% 15.0% 15.0% 13.0% 10.0% 5.0% 16.8% 15.0% 19.9% 20.1% 17.8% -3.8% 0.1% 31.8% -10.2% -15.0% -15.0% -13.0% -10.0% -8.0% -13.4% -5.0% -5.0% -5.0% -5.0% -5.0% -5.0% 6.5% 0.2% 2.0% 2.0% 2.0% 2.0% 2.0% -1.2% -1.9% -2.0% -2.0% -2.0% -2.0% -2.0% 5.6% 12.9% 12.0% 12.0% 12.0% 12.0% 12.0% -9.5% -5.6% -5.0% -5.0% -5.0% -5.0% -5.0% 6.3% 16.7% 12.0% 12.0% 12.0% 12.0% 12.0% 19.2% 19.5% 19.5% 15.0% 10.0% 5.0% 5.0% -14.3% -49.8% -5.0% -5.0% -5.0% -5.0% -5.0% -12.1% 9.2% 7.0% 10.0% 5.0% 8.0% 10.0% 20.0% 20.0% 20.0% 20.0% 5.4% 2.2% 11.2% 16.6% 12.1% -1.2% 2.0% Forecasted Figures in millions Net sales % growth Cost of products sold % of Sales Gross Profit % margin 2014E 2015E 2016E 2017E 2018E $20,903.08 $24,369.67 $27,327.36 $27,011.10 $27,545.22 11% 17% 12% -1% 2% $4,598.68 $5,361.33 $6,012.02 $5,942.44 $6,059.95 22.00% 22.00% 22.00% 22.00% 22.00% $16,304.41 $19,008.34 $21,315.34 $21,068.66 $21,485.27 78.00% 78.00% 78.00% 78.00% 78.00% Selling, general and administrative % of Sales Research and development % of Sales Acquired in-process research and development % of Sales EBIT % Margin $7,589.16 28.46% $3,167.71 15.15% $397.20 1.90% $5,150.35 24.64% $6,935.77 28.46% $3,693.04 15.15% $463.07 1.90% $7,916.46 32.48% $7,777.55 28.46% $4,141.26 15.15% $519.27 1.90% $8,877.26 32.48% $7,687.54 28.46% $4,093.33 15.15% $513.26 1.90% $8,774.53 32.48% $7,839.55 28.46% $4,174.27 15.15% $523.41 1.90% $8,948.04 32.48% Interest expense, net % of Sales Net foreign exchange (gain) loss % of Sales Other (income) expense, net % of Sales EBT % Margin Income tax expense % Tax Rate $282.11 1.48% $39.72 0.19% ($22.62) -0.11% $4,851.14 23.21% $417.25 22% $286.43 1.53% $46.30 0.19% ($26.37) -0.11% $7,610.10 31.23% $1,674.22 22% $290.96 1.58% $51.92 0.19% ($29.57) -0.11% $8,563.96 31.34% $1,884.07 22% $295.70 1.63% $51.32 0.19% ($29.23) -0.11% $8,456.74 31.31% $1,860.48 22% $300.67 1.68% $52.34 0.19% ($29.81) -0.11% $8,624.84 31.31% $1,897.47 22% Net earnings % Margin $4,433.89 21.21% $5,935.88 24.36% $6,679.89 24.44% $6,596.26 24.42% $6,727.38 24.42% Discounted Cash Flow Analysis Discounted Cash Flow Analysis 2014 2015 2016 2017 Net Income $4,434 $5,936 $6,680 $6,596 $6,727 Depreciation & Amortization $1,353 $1,578 $1,769 $1,749 $1,783 CapEx ($418) ($487) ($547) ($540) ($551) $837 $887 $758 $32 $130 FCF $4,532 $6,139 $7,144 $7,772 $7,829 $113,115 PV FCF $4,115 $5,062 $5,349 $5,284 $4,833 Change NWC Implied Equity Value $94,467 Discount rate Less Debt $14,292 Terminal Value Growth Rate Implied Market Cap $80,175 Current Share Outstanding 1,593.50 Estimated Share Buy Back 40 Estimated Share Outstanding 1,553.5 Implied share price $51.61 2018 Terminal $69,825 10.13% 3.00% Scenario Analysis Sensitivity Analysis Discount rate lost on Humira sales on 2016 #### 9.17% 9.67% 10.17% 10.67% 11.17% 11.67% -5% $63.50 $57.87 $53.04 $48.84 $45.15 $41.89 -10% $62.40 $56.88 $52.13 $48.00 $44.38 $41.18 -15% $61.31 $55.89 $51.22 $47.17 $43.61 $40.46 -20% $60.22 $54.90 $50.32 $46.33 $42.84 $39.75 -25% $59.13 $53.90 $49.41 $45.50 $42.07 $39.04 -30% $58.04 $52.91 $48.50 $44.66 $41.30 $38.32 -35% $56.94 $51.92 $47.59 $43.83 $40.53 $37.61 -40% $55.85 $50.92 $46.68 $43.00 $39.76 $36.90 Comparable Companies Analysis Target Company AbbVie Inc. Last Close Dividend Price/ Price/ Market Cap Yields Sales Book P/E Forward P/E TEV/ EBIT EBIT/EV $56.90 90,670 3.1% 4.83 17.17 22.05 14.66 14.8 6.6% Comparable Companies Bristol-Myers Squibb Company $51.84 85,946 2.8% 5.25 5.62 32.2 29.29 24.7 3.4% Eli Lilly and Company $64.68 69,001 3.1% 2.99 3.85 20.54 20.66 16.1 8.0% Merck & Co. Inc. $55.51 160,124 3.3% 3.64 3.31 29.25 15.55 16.8 5.4% Pfizer Inc. $28.30 179,447 3.7% 3.48 2.34 17.78 12.69 11.3 9.3% AstraZeneca PLC $69.36 87,588 2.6% 3.41 3.96 42.91 16.73 15.4 7.4% $101.22 285,471 2.8% 4.00 3.63 16.76 16.33 12.7 7.0% Johnson & Johnson Multiple Weight Price/ Sales Forward P/E TEV/EBIT Graham Ratio ABBV Implied Stock Price Implied ABBV Stock Price 25% 25% 25% 25% $41.95 $64.16 $51.58 $57.12 $53.70 Decision? HOLD Valuation Summary Weight Price DCF 50% $ 51.61 Comparable 50% $ 53.70 $ 52.65 Main Reasoning? - Strong growth prospects with Hepatitis C drug - Uncertainty involved with Humira patent expiration - Pipeline in general is strong - Intrinsic value is less than market price - Poor management Questions?